- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04837807
Digital Device Users Who Are Treated With Systane Hydration PF
Understanding Quality of Life in High Digital Device Users Who Are Treated With Systane Hydration PF
Study Overview
Detailed Description
Extensive computer use is no longer an employment-specific challenge. Use of digital devices in work, home, and leisure settings is now the norm, and it is now socially expected. While the introduction of high-powered computers and digital devices have greatly improved many aspects of modern life, the pervasive use of digital devices has caused some patients to develop a condition known as Digital Eye Strain (DES). DES has been reported to be as high as 93% the population depending upon how the condition is defined, and its severity has been found to increase with increased digital device time. DES is a condition where patients experience symptoms such as glare, accommodative dysfunction, defocus, fatigue, discomfort, and dryness from digital device use, and these dry eye symptoms may also result in decreased quality of life. While dryness symptoms in DES are likely multifactorial (e.g., contact lens use, systemic disease status), much of the dryness symptoms in DES are probably due to tear film evaporation secondary to having a reduced number of blinks per minute while using digital devices. Since much of the ocular symptoms associated with DES stem from excessive tear evaporation, artificial tears have become an accepted DES treatment
Systane Hydration PF is a recently released preservative-free artificial tear that is able to supplement the ocular surface's moisture while simultaneously soothing the eye. Systane Hydration PF has HydroBoost technology, which is thought to enhance the drop's effectiveness by incorporating ingredients that increase drop retention. While Systane Hydration PF should in theory improve the symptoms and subsequently the quality of life of patients who have DES, this clinical application has yet to be tested. This drop furthermore is available in both unit-dose and multi-dose options; however, it is unclear if patient perceive a difference between the two dispensing methods. Therefore, the primary purpose of this study is to recruit patients who have DES and to treat them with Systane Hydration PF and determine how regular use of this drop impacts a patient's ocular surface symptoms and overall quality of life. This study will secondarily compare the two dispensing methods to determine if patients prefer one method over the other.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Using digital devices 8 or more hours per day
- Eyes that are dry, irritated, itchy or burn while using a digital screen, like a computer or smartphone
- Eye fatigue from digital screen use
- Impact of Dry Eye on Daily Life (IDEEL) Work score ≤80
- Ocular Surface Disease Index (OSDI) score between 13 and 32 (inclusive)
- Willing to discontinue current artificial tears for at least 24 hours before enrollment
Exclusion Criteria:
- Pregnant or breastfeeding
- Are currently using isotretinoin-derivatives or other ocular medications
- Having any active ocular infection or inflammation
- History of severe ocular trauma
- Ocular surgery within the past 12 months
- Having any known systemic health conditions that are thought to alter tear film physiology (e.g., Sjögren's syndrome
- Using a dry eye treatment other than artificial tears
- Currently using artificial tears more than 4 times per day
- Contact lens wear within the past week
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Unit Dose First, Then Multi-Dose
Subjects randomized to this group will apply the unit-dose version of Systane Hydration PF to determine if it helps alleviate symptoms associated with digital eye strain.
|
This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
|
EXPERIMENTAL: Multi Dose, Then Unit Dose
Subjects randomized to this group will apply multi-dose version of Systane Hydration PF to determine if it helps alleviate symptoms associated with digital eye strain.
|
This is an over-the-counter preservative free artificial tear that can be purchased at most retail stores and pharmacies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IDEEL (Impact of Dry Eye on Daily Life) Quality of Life - Work Subsection
Time Frame: 2 weeks
|
Impact of Dry Eye on Daily Life (IDEEL) Work questions will be self-administered electronically to understand how treatment with Systane Hydration PF helps a patient's ability to work (0-100 scale with 100 being worst and 0 being best).
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drop Dispensing Method Preference
Time Frame: Between groups at 2 weeks
|
Subjects will report whether they preferred the unit-dose dispensing method or the multi-dose dispensing method via a forced choice questionnaire (forced choice with patient being required to pick if they like the unit-dose dispensing method or the multi-dose better).
|
Between groups at 2 weeks
|
Ocular Surface Disease Index (OSDI) Questionnaire
Time Frame: 2 weeks
|
The Ocular Surface Disease Index (OSDI) will be self-administered electronically to understand how treatment with Systane Hydration PF helps a patient's ability to work (0-100 scale with 100 being worst and 0 being best).
|
2 weeks
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-30007063
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye
-
Gordon Schanzlin New VisionRecruitingDry Eye | Dry Eye Disease | Evaporative Dry Eye | Kerato Conjunctivitis Sicca | Evaporative Dry Eye Disease | Dry Eye, EvaporativeUnited States
-
Kao (Taiwan) CorporationChang Gung Memorial HospitalCompletedEye Fatigue | Dry Eye SymptomTaiwan
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Centre for Contact Lens ResearchCoopervision, Inc.CompletedContact Lens Related Dry EyeCanada
-
Alcon ResearchCompletedVisual Performance | Dry Eye Symptoms
-
Alcon ResearchCompletedModerate to Severe Dry Eye
-
Singapore National Eye CentreCompleted
-
Singapore National Eye CentreCompleted
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
Clinical Trials on Systane Hydration PF
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Scripps Poway Eyecare and OptometrySengiRecruiting
-
Ain Shams UniversityCompletedGastrointestinal Motility and Defecation ConditionsEgypt
-
University of California, BerkeleyAlcon ResearchCompleted
-
Ain Shams UniversityCompleted
-
Kaiser PermanenteCompletedContrast Medium-induced NephropathyUnited States
-
Guangdong Provincial People's HospitalPeking University First Hospital; Xijing Hospital; Fudan University; Beijing Friendship... and other collaboratorsCompletedChronic Kidney DiseaseChina